Skip to main content
. 2024 Sep 26;2024(9):CD006689. doi: 10.1002/14651858.CD006689.pub3

Comparison 7. Azithromycin (AZ) versus sulfadoxine‐pyrimethamine (SP).

Outcome or subgroup title No. of studies No. of participants Statistical method Effect size
7.1 Maternal peripheral parasitaemia at delivery (blood smear) 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 0.90 [0.32, 2.52]
7.2 Maternal anaemia at delivery 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 1.16 [0.53, 2.52]
7.3 Placental malaria (blood smear) 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 3.15 [0.34, 29.45]
7.4 Clinical malaria episodes during pregnancy 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 1.44 [0.84, 2.47]
7.5 Low birth weight (< 2.5 kg) 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 2.10 [0.55, 8.02]
7.6 Mean birth weight (in kg) 1 123 Mean Difference (IV, Fixed, 95% CI) ‐0.06 [‐0.17, 0.05]
7.7 Prematurity 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.27, 4.01]
7.8 SAEs during pregnancy 1 123 Risk Ratio (M‐H, Fixed, 95% CI) Not estimable
7.9 Spontaneous abortion 1 123 Risk Ratio (M‐H, Fixed, 95% CI) Not estimable
7.10 Stillbirth 1 123 Risk Ratio (M‐H, Fixed, 95% CI) Not estimable
7.11 Congenital malformations 1 123 Risk Ratio (M‐H, Fixed, 95% CI) Not estimable
7.12 Maternal mortality 1 123 Risk Ratio (M‐H, Fixed, 95% CI) Not estimable
7.13 Neonatal mortality 1 123 Risk Ratio (M‐H, Fixed, 95% CI) Not estimable
7.14 Adverse events: headache 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 0.18 [0.02, 1.41]
7.15 Adverse events: nausea 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 7.35 [0.93, 57.97]
7.16 Adverse events: vomiting 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 2.10 [0.20, 22.56]
7.17 Adverse events: dizziness 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 0.42 [0.08, 2.08]
7.18 Adverse events: abdominal pain 1 123 Risk Ratio (M‐H, Fixed, 95% CI) 1.05 [0.07, 16.41]